Onset: 60-90 min after fasted dose; 2-4 hr if taken with food. Peak effect window: 3-6 hr post-dose for cognitive enhancement. Effective wakefulness window: 12-14 hr.

Characteristic feel:

• Less of a "kick" or "peak" than modafinil — described as a smooth elevation with no euphoric edge
• More "glide" through the workday with steadier focus
• Less of the modafinil "afternoon shoulder" (the slight dip when S-enantiomer clears)
• Late-day persistence: at 6-8 PM, plasma armodafinil is meaningfully higher than equivalent modafinil; users notice they are "still on" much later
• Some users report it feels more like a clean alertness, less anxiogenic than modafinil for them; others report the opposite (more anxious because longer)
• Cognitive enhancement (decision-making, planning, sustained attention) appears equivalent to modafinil in healthy users; benefits more pronounced in sleep-restricted than well-rested individuals

Variability: High inter-individual variation. Frontiers in Pharmacology 2025 (Hansen et al.) showed stable interindividual differences in modafinil vigilance response — same person responds consistently across exposures, but between-person response varies substantially. CYP3A4 induction status, CYP2C19 polymorphism, body mass, and prior caffeine adaptation all modulate.

• Tolerance buildup: minimal-to-low. This is one of armodafinil's strongest selling points. 12-month open-label data shows wakefulness improvements maintained from month 1 throughout study. Narcolepsy patients use daily for years without dose escalation.
• The tolerance debate: Clinical data consistently shows no meaningful tolerance for therapeutic narcolepsy/OSA use. Anecdotal nootropic-community reports of "modafinil tolerance" likely reflect (a) initial novelty effect fading, (b) sleep debt accumulation that the drug masks, or (c) genuine but modest receptor desensitization with very high-dose chronic use. The 2023 study on pitolisant-bridging for "modafinil tolerance reset" exists but doesn't establish that conventional armodafinil tolerance is a real phenomenon at therapeutic doses.
• Recommended cycle for users in this archetype: 5 days/week (M-F) with weekend washout to preserve receptor sensitivity and verify no sleep-debt masking is occurring. This matches modafinil cycle protocol.
• Reset protocol if needed: 7-10 day full break is sufficient to clear any tolerance. Some users implement a 1-week pause every 8-12 weeks as insurance.

Synergistic with

• caffeine (low dose, 50-100 mg): Adenosine antagonism is mechanistically additive to dopamine/orexin/histamine arousal. the user's baseline has zero caffeine, so 50 mg with armodafinil could be a strong combo for high-output mornings — but stack caution because both extend wakefulness window.
• L-theanine 200 mg: Smooths the alerting edge, no efficacy compromise.
• bromantane: Different mechanism (mild DA + 5-HT + DAT, anti-asthenic). Stacks cleanly per Russian eugeroic protocols. This is part of the canonical stack plan.
• citicoline / Alpha-GPC: Cholinergic substrate support for the cognitive load that modafinil-class drugs let you sustain.
• bupropion (if Rx-path): 6 RCTs back modafinil + bupropion for depression/fatigue; same mechanism logic applies to armodafinil + bupropion.
• omega-3 / DHA: General brain substrate; no interaction.

Avoid stacking with

• MAOIs (selegiline >10 mg, tranylcypromine, phenelzine): Hypertensive crisis risk. Note for users in this archetype: Selegiline 1-2.5 mg/day is MAO-B selective only and clinically considered safe with modafinil-class drugs, but stay below 5 mg/day strictly to avoid losing selectivity. The V5 plan's selegiline 1-2.5 mg AM is fine; do not escalate.
• classical stimulants (amphetamine, methylphenidate, focalin): Stacking dopaminergic stimulants → overstimulation, cardiovascular load, anxiety, sleep wreck. Pick one.
• 9-Me-BC + bromantane + armodafinil triple-stack: 3 dopaminergic agents = overstimulation risk per encyclopedia.
• other eugeroics (modafinil, solriamfetol, pitolisant): Redundant + AUC stacking. Pick one wakefulness anchor.
• hormonal contraceptives (irrelevant for users in this archetype, but flag): CYP3A4 induction reduces effectiveness ~18%.

Neutral / safe co-administration

• All of the canonical stack: NAC, citicoline, magnesium glycinate/threonate, fish oil/DHA, phosphatidylserine, curcumin, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, vitamin C — no known interactions
• Creatine
• Adamax / Semax / Selank intranasal peptides
• Cerebrolysin IM (different pathway entirely)
• BPC-157 / TB-500 peptides

Armodafinil's CYP profile:

• Moderate inducer of CYP3A4 — reduces blood levels of CYP3A4 substrates: hormonal contraceptives (~18% decrease — primary contraceptive failure mechanism), cyclosporine, midazolam, triazolam, certain statins, certain anti-epileptics, certain protease inhibitors. Use barrier or non-hormonal contraception during therapy and for 1 month after discontinuation.
• Moderate inhibitor of CYP2C19 — raises blood levels of CYP2C19 substrates: diazepam, phenytoin, propranolol (the user's PRN propranolol is CYP2D6 mainly but has 2C19 secondary path — be aware), omeprazole/esomeprazole, clopidogrel (which becomes less effective via inhibited activation), some SSRIs (citalopram).
• Weak inducer of CYP1A2 (less clinically meaningful than modafinil's CYP1A2 induction).
• No clinically significant effect on CYP2D6 at therapeutic doses.

Specific interactions worth flagging for users in this archetype:

• Propranolol 20 mg PRN (V5 list): Armodafinil's CYP2C19 inhibition will modestly raise propranolol exposure. At 20 mg PRN this is unlikely to be clinically significant but is worth knowing if HR/BP are unexpectedly low post-presentation dose.
• Selegiline 1-2.5 mg AM (planned V5): Below 5 mg = MAO-B selective only. Safe co-administration. Do not exceed 5 mg/day with armodafinil onboard.
• Bupropion (if added later): Bupropion is CYP2B6 substrate primarily, no major interaction with armodafinil.
• Caffeine: Caffeine is CYP1A2 substrate; armodafinil is weak CYP1A2 inducer. May slightly accelerate caffeine clearance — clinically minor.

Contraceptive failure risk: Highly relevant for partnered users. Increases pregnancy risk for ~1 month after discontinuation due to enzyme induction wash-out. Not directly relevant to the user personally but the user's partners (current/future) should be informed.

• CYP3A4 polymorphism: CYP3A4*22 carriers have reduced enzyme activity → potentially higher armodafinil exposure (and slower induction kinetics on contraceptives). 23andMe doesn't directly report CYP3A4 status comprehensively but pharmacogenomic third-party tools (Promethease, GeneSight) can.
• CYP2C19 polymorphism: *2 and *3 = loss-of-function (poor metabolizer phenotype), present in ~3% of Caucasians. *17 = gain-of-function (ultrarapid). Since armodafinil inhibits CYP2C19, PMs of CYP2C19 substrates (clopidogrel, citalopram) experience compounded effects. Relevant if the user eventually takes those substrates.
• CYP1A2 polymorphism: *1F = inducible variant, common. the user's caffeine response may vary based on this; armodafinil's CYP1A2 induction is mild but additive.
• No specific HLA marker is established for armodafinil-induced SJS, unlike carbamazepine (HLA-B*1502 in Asian populations). Standard SJS surveillance applies regardless of genotype.
• Action item for users in this archetype: Once 23andMe results land in June 2026, run through Promethease or similar to extract CYP3A4, CYP2C19, CYP1A2 status. Adjust starting dose downward if PM phenotype on either CYP3A4 or CYP2C19.

Strategic note for users in this archetype: Order Artvigil 150 mg from ModafinilXL for first A/B test. Cheaper than Waklert with no clinical difference. 30 pills = 30 day supply if 1/day or 60 day supply if 1/2-tab. Place order ~2 weeks before week-8 A/B start to account for shipping delays. Do not co-order with modafinil shipment to keep customs profile minimal (combined orders sometimes flagged).

Vendor change since prior context:

• BuyModa CLOSED MAY 2025 — do not attempt order from this vendor.
• AfinilExpress closed 2019-2023 — defunct.
• DuckDose closed — defunct.
• Done telehealth criminally convicted Nov 2025 — defunct.
• Cerebral dropped modafinil from formulary — paid $3.6M settlement, conservative formulary now.
• ModafinilXL and HighStreetPharma are the two surviving high-reliability vendors as of 2026-05.

Customs note: Personal-use modafinil/armodafinil import is a gray area legally in the US. Schedule IV technically requires Rx for import, but personal-use small quantities (<90 day supply) are rarely seized; reships are typical when a package is held. Order in 30-90 day chunks, not bulk 6-month orders, to limit exposure.

Baseline (before starting)

• Liver panel: ALT, AST, ALP, GGT, bilirubin — armodafinil is hepatically metabolized; baseline establishes any pre-existing dysfunction
• CBC + comprehensive metabolic panel
• Resting HR (Oura ongoing) + cuff BP
• Sleep architecture baseline (Oura): TST, sleep onset latency, REM %, deep %
• HRV overnight average (Oura) — 14-day baseline
• Subjective alertness baseline scores (9 AM, 1 PM, 5 PM, 9 PM × 7 days)
• Body weight

During use

• Liver enzymes (ALT/AST): 8-week mark, then quarterly. Modafinil family rarely causes hepatotoxicity but worth verifying.
• BP cuff: weekly first month, then monthly
• Resting HR (Oura): daily — flag if >5 bpm sustained increase from baseline
• Sleep onset latency (Oura): daily — flag if >45 min consistently
• Total sleep time (Oura): daily — flag if loss >30 min from baseline
• HRV (Oura): daily — sustained >10% drop is meaningful
• Subjective alertness (logged scale): daily
• Skin/mucosal check: weekly first 8 weeks for SJS surveillance

Post-cycle (if cycled)

• Re-baseline sleep architecture during 7-10 day washout
• Confirm HR/BP return to baseline within 1 week of discontinuation
• Liver panel recheck if any abnormalities seen during use